Novartis' JAK inhibitor Jakavi patient populations to come under NICE microscope
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, is to review Novartis/Incyte's orphan myelofibrosis treatment, Jakavi (ruxolitinib). The institute's draft appraisal scope, now out for consultation, indicates that the institute will be paying close attention to whether it can narrow the potential patient population.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.